Of note was the observed upregulation of the Myd88-dependent toll-like receptor signaling pathway which is in good agreement with recent studies that demonstrated amelioration of local and systemic SS disease manifestations upon the loss of Myd88 expression in the NOD.B10 mouse model (30–32). Here, MYD88 is linked to synovial sarcoma.